Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.33 USD | -2.09% | -7.93% | -27.20% |
Financials (USD)
Sales 2024 * | 529M | Sales 2025 * | 681M | Capitalization | 3.05B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 121M | EV / Sales 2024 * | 6.03 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.52 x |
P/E ratio 2024 * |
-3,029
x | P/E ratio 2025 * |
26.4
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.75% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | -2.09% | ||
1 week | -7.93% | ||
Current month | -12.31% | ||
1 month | -10.79% | ||
3 months | -16.83% | ||
6 months | -3.00% | ||
Current year | -27.20% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 61 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 16 M€ | -8.26% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 10.33 | -2.09% | 1,725,749 |
24-04-17 | 10.55 | -0.09% | 3,013,059 |
24-04-16 | 10.56 | -0.94% | 2,800,442 |
24-04-15 | 10.66 | -0.19% | 2,750,920 |
24-04-12 | 10.68 | -4.81% | 2,248,224 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.20% | 3.05B | |
-1.82% | 41.35B | |
+44.25% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- FOLD Stock